trihexyphenidyl
Adjunctive therapy • Brands: Artane
Last reviewed: 2025-12-30
General information
- Primary label indications include: Parkinsonism (label).
- Class: Adjunctive therapy
- Common US brands: Artane
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2025-12-30
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Anticholinergic (antimuscarinic) antiparkinson agent used for parkinsonism and to manage extrapyramidal reactions to antipsychotics. It can improve drug-induced parkinsonism and acute dystonia, but does not treat tardive dyskinesia and may worsen it; anticholinergic adverse effects often limit use.
Metabolism & Half‑life
- Metabolism: Hepatic metabolism (extent not well characterized in current labeling) (label/clinical).
- Half‑life: —
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- Trihexyphenidyl hydrochloride tablets prescribing information — DailyMed (2023)
- Recognition and Management of Antipsychotic-Induced Parkinsonism in Older Adults A Narrative Review — Medicines (2021)
- Managing Antipsychotic-Induced Acute and Tardive Dystonia — Drug Safety (1998)
- Anticholinergic Burden and Cognitive Performance in Patients With Schizophrenia A Systematic Literature Review — Frontiers in Psychiatry (2021)
- AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology — Pharmacopsychiatry (2018)